Your browser doesn't support javascript.
loading
The European Medicines Agency assessment of mavacamten as treatment of symptomatic obstructive hypertrophic cardiomyopathy in adult patients.
DeVries, J Hans; Irs, Alar; Hillege, Hans L.
Affiliation
  • DeVries JH; Seconded National Expert, European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS Amsterdam, the Netherlands.
  • Irs A; Department of Internal Medicine, Amsterdam UMC, Locatie AMC, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands.
  • Hillege HL; CHMP member, State Agency of Medicines, Tartu, Estonia.
Eur Heart J ; 44(37): 3492-3494, 2023 10 01.
Article in En | MEDLINE | ID: mdl-37482673
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiomyopathy, Hypertrophic Type of study: Diagnostic_studies Limits: Adult / Humans Language: En Journal: Eur Heart J Year: 2023 Document type: Article Affiliation country: Netherlands
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cardiomyopathy, Hypertrophic Type of study: Diagnostic_studies Limits: Adult / Humans Language: En Journal: Eur Heart J Year: 2023 Document type: Article Affiliation country: Netherlands